Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Axsome Therapeutics (AXSM) Current Leases: 2022-2025

Historic Current Leases for Axsome Therapeutics (AXSM) over the last 4 years, with Sep 2025 value amounting to $2.5 million.

  • Axsome Therapeutics' Current Leases rose 53.47% to $2.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.5 million, marking a year-over-year increase of 53.47%. This contributed to the annual value of $1.8 million for FY2024, which is 44.83% up from last year.
  • Axsome Therapeutics' Current Leases amounted to $2.5 million in Q3 2025, which was up 23.98% from $2.0 million recorded in Q2 2025.
  • Over the past 5 years, Axsome Therapeutics' Current Leases peaked at $2.5 million during Q3 2025, and registered a low of $108,000 during Q1 2023.
  • In the last 3 years, Axsome Therapeutics' Current Leases had a median value of $1.4 million in 2024 and averaged $1.3 million.
  • Per our database at Business Quant, Axsome Therapeutics' Current Leases slumped by 88.83% in 2023 and then surged by 967.59% in 2024.
  • Quarterly analysis of 4 years shows Axsome Therapeutics' Current Leases stood at $425,000 in 2022, then skyrocketed by 198.12% to $1.3 million in 2023, then spiked by 44.83% to $1.8 million in 2024, then skyrocketed by 53.47% to $2.5 million in 2025.
  • Its Current Leases was $2.5 million in Q3 2025, compared to $2.0 million in Q2 2025 and $1.8 million in Q1 2025.